Skip to main content
OpenTrials
Completed

NCT Number: NCT03097211

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

The purpose of this study was to determine whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose of immediate release levodopa/benserazide 200/50 mg or with a single-dose of immediate release levodopa/benserazide 200/50 mg plus a single-dose of nebicapone 150 mg.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Human Pharmacology Unit (UFH) - BIAL - Portela & Cª, SA

S. Mamede Do Coronado, 4745-457, Portugal

About this study

Single centre, double-blind, randomised, placebo-controlled, rising multiple dose study in four sequential groups of healthy male and female subjects. Eligible subjects were admitted to the Human Pharmacology Unit (UFH)on the day prior to receiving the first study medication. Starting in the morning of Day 1 (first dose), subjects received BIA 6-512/Placebo thrice daily until the morning of Day 5 (last dose). Concomitantly with the morning dose of BIA 6-512/Placebo on Day 4, a levodopa/benserazide 200/50 mg (Madopar® 250) single-dose was administered. On Day 5, a Madopar® 250 single-dose and a nebicapone 150 mg single-dose were administered concomitantly with the morning dose of BIA 6-512/Placebo. In the morning of Day 4 and Day 5, products were administered in fasting conditions of at least 8 hours and subjects remained fasted until 2 h post-dose. Subjects were resident in the UFH from admission (Day 0) until at least 24 h post last dose (Day 6); then, they were discharged and returned for the follow-up visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects aged between 18 and 45 years, inclusive.
  • Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive.
  • Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.
  • Subjects who had negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening
  • Subjects who had clinical laboratory test results clinically acceptable at screening and admission.
  • Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission.
  • Subjects who were non-smokers or who smoked ≤ 10 cigarettes or equivalent per day.
  • Subjects who were able and willing to gave written informed consent.
  • (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence.
  • (If female) She had a negative urine pregnancy test at screening and admission.

Exclusion criteria

  • Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
  • Subjects who had a clinically relevant surgical history.
  • Subjects who had a clinically relevant family history.
  • Subjects who had a history of relevant atopy.
  • Subjects who had a history of relevant drug hypersensitivity.
  • Subjects who had a history of alcoholism or drug abuse.
  • Subjects who consumed more than 14 units of alcohol a week.
  • Subjects who had a significant infection or known inflammatory process on screening or admission.
  • Subjects who had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission.
  • Subjects who had used medicines within 2 weeks of admission that may affect the safety or other study assessments, in the investigator's opinion.
  • Subjects who had previously participated in a clinical trial with BIA 6-512.
  • Subjects who had used any investigational drug or participated in any clinical trial within 6 months prior to screening.
  • Subjects who had participated in more than 2 clinical trials within the 12 months prior to screening.
  • Subjects who had donated or received any blood or blood products within the 3 months prior to screening.
  • Subjects who were vegetarians, vegans or have medical dietary restrictions.
  • Subjects who cannot communicate reliably with the investigator.
  • Subjects who were unlikely to co-operate with the requirements of the study.
  • Subjects who were unwilling or unable to give written informed consent.
  • (If female) She was pregnant or breast-feeding.
  • (If female) She was of childbearing potential and she did not use an effective contraceptive method (double-barrier, intra-uterine device or abstinence) or she used oral contraceptives.

Treatment and study plan

Placebo

Drug

Placebo capsules. Orally, with 240 mL of potable water.

BIA 6-512

Drug

The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.

Other names: Trans-resveratrol

Madopar® 250

Drug

Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.

Other names: Levodopa/benserazide

Nebicapone

Drug

Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.

Other names: BIA 3-202

Primary outcomes

  1. Day 4 - Maximum observed plasma drug concentration (Cmax)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose.

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 4

  2. Day 4 - Time of occurrence of Cmax (tmax)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose.

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 4

  3. Day 4 - Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose.

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 4

  4. Day 4 - AUC from time zero to 8 h post-dose (AUC0-τ)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose.

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 4

  5. Day 4 - Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose.

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 4

  6. Day 4 - Apparent terminal elimination half-life, calculated from ln 2/λz (t1/2)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose.

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 4

  7. Day 5 - Maximum observed plasma drug concentration (Cmax)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 5

  8. Day 5 - Time of occurrence of Cmax (tmax)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 5

  9. Day 5 - Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 5

  10. Day 5 - AUC from time zero to 8 h post-dose (AUC0-τ)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 5

  11. Day 5 - Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 5

  12. Day 5 - Apparent terminal elimination half-life, calculated from ln 2/λz (t1/2)

    Time frame: pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose

    Pharmacokinetic parameters of BIA 6-512, levodopa, and nebicapone on day 5

Sponsors and collaborators

Lead sponsor

Bial - Portela C S.A.

Industry

Registry information

Official study title

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Important dates

Study start
2006
Primary completion
2006
Study completion
2006
First posted
Mar 31, 2017
Registry last updated
Mar 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.